Ignite Creation Date:
2024-05-06 @ 4:41 PM
Last Modification Date:
2024-10-26 @ 2:14 PM
Study NCT ID:
NCT05067166
Status:
AVAILABLE
Last Update Posted:
2024-05-03
First Post:
2021-09-23
Brief Title:
Open-Label Expanded Access for Ebola-Infected Patients to Receive Human mAb Ansuvimab as Therapeutic or for HR PEP
Sponsor:
Ridgeback Biotherapeutics LP
Organization:
Ridgeback Biotherapeutics LP
Key Dates - Follows AllAPIJSON File Order
Start Date:
None
Start Date Type:
None
Primary Completion Date:
None
Primary Completion Date Type:
None
Completion Date:
None
Completion Date Type:
None
First Submit Date:
2021-09-23
First Submit QC Date:
September 23 2021
Study First Post Date:
2021-10-05
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-05-02
Last Update Post Date:
2024-05-03
Last Update Post Date Type:
ACTUAL